Royal Philips has announced the Expression MR400, a new technology that monitors patients undergoing magnetic resonance imaging (MRIs), has received 510(k) clearance from the US Food and Drug Administration (FDA). The MR400 provides ICU-comparable, bedside quality monitoring in the MR suite for all patients, including those with serious medical conditions or who require anesthesia.

In the MR suite, strong electromagnetic fields make it impossible for clinicians to use traditional patient monitors without causing complications with the monitor or degradation of the images. The lack of adequate monitoring is particularly problematic for patients, including children, who require anesthesia when getting an MRI. Without the ability to reliably track key vital signs, clinicians may not know a patient is in distress until it is too late.

The MR400 is designed not to create image artifacts or other interferences from the electromagnetic fields when used according to the labeling, ensuring that patients receive the level of clinical care and monitoring they need. Similar to traditional patient monitors, the system uses intelligent alarms to warn clinicians of severe patient changes, including desaturation, apnea, and extreme bradycardia/tachycardia. Clinicians and staff are able to customize the monitor settings for each patient to prioritize warning signals to reduce alarm fatigue.

The new monitoring system uses a touchscreen with the same interface as other Philips' monitors, making it easier for clinicians to view and respond to patient data. The MR400 uses wireless technology, connects with the electronic healthcare record, and shares information with IntelliBridge Enterprise to seamlessly send and receive patient information across the hospital, ensuring that all care team members have access to the same high-quality patient information.


Digital version